Список литературы

1. Ющук Н.Д., Климова Е.А., Знойко О.О. с соавт. Вирусные гепатиты: клиника, диагностика, лечение. 3-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018. 368 с.

2. Кожанова Т.В., Ильченко Л.Ю., Михайлов М.И. Гепатит дельта: этиология, клиника, диагностика, терапия. Архивъ внутренней медицины, 2014, 5: 21-8.

3. Кожанова Т.В., Ильченко Л.Ю., Михайлов М.И. Вирусный гепатит дельта. Существует ли в Российской Федерации проблема дельта-инфекции? Экспериментальная и клиническая гастроэнтерология, 2014, 112: 4-12.

4. Исаева О.В., Кюрегян К.К. Вирусный гепатит дельта: недооцененная угроза. Инфекционные болезни: новости, мнения, обучение. 2019, 8: 72-9.

5. Абдурахманов Д.Т., Есмембетов К.И., Никулкина Е.Н. с соавт. Хронический гепатит дельта: современное состояние проблемы и перспективы лечения. Клиническая фармакология и терапия, 2019, 28: 26-34.

6. Вирусные гепатиты - достижения и новые перспективы. Москва, 19 - 20 сентября 2019 г. Материалы XII Всероссийской научно-практической конференции с международным участием, Москва, ООО "Гепатит инфо", ООО "Медфорум", 2019, 92 с.

7. Исаева О.В., Кожанова Т.В., Ильченко Л.Ю. с соавт. Влияние вакцинации против гепатита B на распространенность гепатита дельта в эндемичном регионе. Инфекционные болезни: новости, мнения, обучение. 2019, 8: 36 - 42.

8. Богомолов П.О., Ивашкин В.Т., Буеверов А.О. с соавт. Эффективность и безопасность булевиртида в лечении хронического гепатита D - результаты рандомизированных контролируемых исследований. Инфекционные болезни, 2020, 18: 153-62.

9. Yurdaydin C., Abbas Z., Buti M. et al. (on behalf of the Hepatitis Delta International Network). Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol, 2019, 70: 1008-15.

10. Mauss S., Berg T., Rockstroh J. et al. Hepatology - A clinical textbook. 10th edition, 2020, 365 p.

11. Yan H., Zhong G., Xu G. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 2012, 1: e00049.

12. Urban S., Bartenschlager R., Kubitz R., Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology, 2014, 147: 48 - 64.

13. Chen H., Shen D., Ji D. et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut, 2018, 68: 381-2.

14. Vlachogiannakos J., Papatheodoridis G. New epidemiology of hepatitis delta. Liver International. 2020, 40 (Suppl. 1): 48 - 53.

15. Da B., Heller T., Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterology Report, 2019, 7(4): 231-45.

16. Miao Z., Zhang S., Ou X. et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis., 2020, 221: 1677-87.

17. Fattovich G., Giustina G., Christensen E. et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut, 2000, 46: 420-6.

18. Westbrook R., Dusheiko G. Natural history of hepatitis C. J Hepatol, 2014, 61: S58 - 68.

19. Sarin S., Kumar M., Lau G. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10: 1 - 98.

20. Lampertico P., Agarwal K., Berg T. et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-98.

21. Terrault N., Lok A., McMahon B. et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67: 1560-99.

22. Do A., Reau N. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatology Communications, 2020, 4: 329-41.

23. Galle P., Forner A., Llovet J. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69: 182 - 236.

24. Blank A., Markert C., Hohmann N. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol, 2016, 65: 483-9.

25. Li W., Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol, 2016, 64(1 Suppl): S32 - S40.

26. Shah P., Choudhry S., Reyes K. et al. An update on the management of chronic hepatitis D. Gastroenterol Report, 2019, 7: 396 - 402.

27. Mentha N., Clement S., Negro F., Alfaiate D. A review on hepatitis D: from virology to new therapies. J Adv Res, 2019, 17: 3 - 15.

28. Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol, 2019, 25: 4567-795.

29. Asselah T., Loureiro D., Tout I. et al. Future treatments for hepatitis delta virus infection. Liver Int, 2020, 40, suppl 1: 54 - 60.

30. Bogomolov P., Alexandrov A., Voronkova N. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol, 2016, 65: 490-8.

31. Wedemeyer H., Bogomolov P., Blank A. et. al. Final results of a multicenter open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV infection. J Hepatol, 2018, 68: S3 (GS-005).

32. Wedemeyer H. et al. Clinical study report. A multicenter, open-label, randomized clinical study to assess efficacy and safety of 3 doses of Myrcludex B for 24 weeks in combination with Tenofovir compared to Tenofovir alone to suppress HBV replication in patients with chronic hepatitis D. Final version 1.0, 10.09.2019 г., 145 p.

33. Wedemeyer H., Sch neweis K., Bogomolov P. et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol, 2019, 70: e81.

34. Bogomolov P.O. et al. Clinical study report, groups A-D. A multicentre, open-label, randomized, comparative, parallel-arm phase II study to assess efficacy and safety of Myrcludex B in combination with peginterferon alfa-2a versus peginterferon alfa-2a alone in patients with chronic viral hepatitis B with delta-agent. Final version 1.0, 11.09.2019 г., 141 p.

35. Wranke A., Serrano B., Heidrich B. et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology, 2017, 65: 414-25.

36. Wedemeyer H., Yurdayd n C., Dalekos et al. HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med, 2011, 364: 322-31.

37. Heidrich B., Yurdayd n C., Kaba am G. et al. HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology, 2014, 60: 87-97.

38. Wedemeyer H., Yurdaydin C., Hardtke S. et al. HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis, 2019, 19: 275-86.

39. Goyal A., Murray J. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS ONE, 2014, 9: e110143.